Investors

Home / Investors / Press Releases

Press Releases

16Mar

CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update

9Mar

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

1Mar

CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

6Feb

CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

30Jan

CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

24Jan

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

23Jan

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

8Jan

CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

14Nov

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update

7Nov

CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

RSS
Show All

Contact Info

  • 7575 Gateway Blvd., Suite 110
    Newark, CA 94560
  • +1 (510) 293-8800
  • +1 (510) 293-9090

Quick Links

Pipeline